https://openbell.ai/ 2026-11-07T18:38:21.024Z hourly 1.0 https://openbell.ai/support 2026-11-07T18:38:21.024Z monthly 0.7 https://openbell.ai/privacy 2026-11-07T18:38:21.024Z monthly 0.5 https://openbell.ai/terms 2026-11-07T18:38:21.024Z monthly 0.5 https://openbell.ai/feed.json 2026-11-07T18:38:21.024Z hourly 0.8 https://openbell.ai/news/GOVX:1794060318000 2026-11-07T14:05:18.000Z daily 0.9 https://cdn.brandfetch.io/GOVX/w/400/h/400?c=1idopYfmtR7ZKg8QMud GeoVax Labs Terminates CEO David A. Dodd for Cause GeoVax Labs terminated David A. Dodd as president and CEO effective immediately, citing his refusal to comply with Board-approved directives. Dodd remains a director and Board chairman. The company said it does not intend to provide severance or full option vesting, though the determination of cause may be subject to legal or arbitration review. https://openbell.ai/news/KPTI:1794060308000 2026-11-07T14:05:08.000Z daily 0.9 https://cdn.brandfetch.io/KPTI/w/400/h/400?c=1idopYfmtR7ZKg8QMud Karyopharm Therapeutics Receives Nasdaq Delisting Notice Following Chapter 11 Filing Nasdaq notified Karyopharm Therapeutics on November 4, 2026, that it would delist the company’s securities following its Chapter 11 filing; Karyopharm will not appeal. Trading is scheduled to be suspended at the market open on November 11, after which the shares are expected to trade over the counter as KPTIQ. The bankruptcy plan provides for no distribution to common or preferred stockholders, and the company expects its existing equity securities to have no value. https://openbell.ai/news/CELZ:1794060299000 2026-11-07T14:04:59.000Z daily 0.9 https://cdn.brandfetch.io/CELZ/w/400/h/400?c=1idopYfmtR7ZKg8QMud Creative Medical Technology Holdings Reports 3Q 2026 Financial Results Creative Medical Technology Holdings reported no revenue in the third quarter of 2026, unchanged from a year earlier. Its net loss widened as research and development expenses rose 244% to $1.6 million, including $1.17 million in stock-based expenses tied to its BioDefense investment and higher development costs across other platforms; lower ADAPT trial expenses partly offset the increase. General and administrative expenses climbed 43% to $1.1 million, driven by higher compensation and legal fees. https://openbell.ai/news/ELEF:1794060295000 2026-11-07T14:04:55.000Z daily 0.9 https://cdn.brandfetch.io/ELEF/w/400/h/400?c=1idopYfmtR7ZKg8QMud Silver Elephant Mining Wins Ruling Reversing Pulacayo-Paca Contract Cancellation Bolivia’s Supreme Tribunal of Justice ruled in favor of Silver Elephant Mining subsidiary Apogee Minerals Bolivia, annulling COMIBOL’s December 16, 2024 cancellation of the Pulacayo-Paca Mining Production Contract. Signed in 2019, the contract grants exclusive rights to develop and mine the silver project for up to 30 years. Silver Elephant was notified of the decision on November 5, 2026; implementation by Bolivian authorities remains pending. https://openbell.ai/news/MERC:1794060287000 2026-11-07T14:04:47.000Z daily 0.9 https://cdn.brandfetch.io/MERC/w/400/h/400?c=1idopYfmtR7ZKg8QMud Mercer International Inc. Reports Third Quarter 2026 Financial Results Mercer International reported third-quarter 2026 Operating EBITDA of negative $2.9 million, improved from negative $28.1 million a year earlier, while its net loss narrowed to $59.2 million, or $0.88 per share, from $80.8 million, or $1.21 per share. The company said its “One Goal One Hundred” program generated $22.0 million in quarterly cost savings. It also cited a previously announced restructuring support agreement involving $1.275 billion in senior notes and $400 million in new capital to strengthen its balance sheet. Pulp results benefited from Peace River mill government grants and higher energy sales realizations, partly offset by planned maintenance and fiber costs. https://openbell.ai/news/INM:1794060284000 2026-11-07T14:04:44.000Z daily 0.9 https://cdn.brandfetch.io/INM/w/400/h/400?c=1idopYfmtR7ZKg8QMud InMed Pharmaceuticals Completes Merger with Mentari Therapeutics InMed Pharmaceuticals completed its merger with privately held Mentari Therapeutics, and the combined company will operate as Mentari Therapeutics, Inc. The company also completed its redomestication from British Columbia to Nevada. Before the merger, Mentari completed private financings totaling approximately $490 million in gross proceeds, including the conversion of $50 million in convertible notes plus accrued interest. The combined company’s shares are expected to begin trading on the Nasdaq Capital Market under ticker MTRI on November 9, 2026. https://openbell.ai/news/XHLD:1794060283000 2026-11-07T14:04:43.000Z daily 0.9 https://cdn.brandfetch.io/XHLD/w/400/h/400?c=1idopYfmtR7ZKg8QMud TEN Holdings Reports Third Quarter 2026 Financial Results TEN Holdings reported third-quarter 2026 revenue of $640,000, up 17.9% year over year, and a net loss of $3.734 million. The loss included a $1.8 million write-off of previously capitalized service contracts and about $500,000 in legal expenses. The company is transitioning from managed services to a recurring subscription-based SaaS model through its TEN Digital Experience Platform, with plans to expand AI, automation, and advanced analytics capabilities. TEN Holdings also adjourned its 2026 Annual Meeting of Stockholders. https://openbell.ai/news/BR:1794060279000 2026-11-07T14:04:39.000Z daily 0.9 https://cdn.brandfetch.io/BR/w/400/h/400?c=1idopYfmtR7ZKg8QMud Big Rock Brewery Inc. Announces Q3 2026 Financial Results and Operational Updates Big Rock Brewery reported third-quarter 2026 net revenue of $12.5 million, down from $13.9 million a year earlier, while sales volume fell 20.7% to 66,251 hl. The company reduced its workforce by 23% as part of cost-cutting measures. It also missed its EBITDA targets as of September 30, prompting the reclassification of $3.5 million in long-term debt as current and an amendment to its Second Lien Financing agreement. https://openbell.ai/news/AWX:1794060279000 2026-11-07T14:04:39.000Z daily 0.9 https://cdn.brandfetch.io/AWX/w/400/h/400?c=1idopYfmtR7ZKg8QMud Avalon Holdings Corporation Announces Third Quarter 2026 Financial Results Avalon Holdings reported third-quarter 2026 net operating revenue of $24.3 million, down from $25.7 million a year earlier. Net income attributable to common shareholders rose to $2.7 million, or $0.69 per basic share, from $1.9 million, or $0.49 per share. For the first nine months of 2026, revenue was $62.9 million and net income was approximately $2.3 million. https://openbell.ai/news/CVR:1794060279000 2026-11-07T14:04:39.000Z daily 0.9 https://cdn.brandfetch.io/CVR/w/400/h/400?c=1idopYfmtR7ZKg8QMud Chicago Rivet & Machine Co. Announces Third Quarter 2026 Results Chicago Rivet & Machine reported a third-quarter 2026 net loss of $915,977, or $0.95 per share, compared with net income of $67,572, or $0.07 per share, a year earlier. Quarterly net sales rose to $7.53 million from $7.36 million. For the first nine months of 2026, the company posted a net loss of $2.27 million, or $2.35 per share, versus net income of $73,615, or $0.08 per share, in the prior-year period. The figures are subject to year-end audit. https://openbell.ai/news/DRUG:1794060264000 2026-11-07T14:04:24.000Z daily 0.9 https://cdn.brandfetch.io/DRUG/w/400/h/400?c=1idopYfmtR7ZKg8QMud Law Firms Initiate Securities Investigations Following FDA Partial Clinical Hold on Bright Minds Biosciences On November 2, 2026, Bright Minds Biosciences disclosed that the FDA had placed a partial clinical hold on its BMB-101 trial, citing toxicity in mice and concerns about pharmacokinetic and juvenile-toxicity data. On November 6, law firms announced investigations into potential securities claims, examining whether the company adequately disclosed the preclinical findings and data limitations to investors. Bright Minds’ stock fell significantly after the clinical-hold announcement. https://openbell.ai/news/CRVO:1794060261000 2026-11-07T14:04:21.000Z daily 0.9 https://cdn.brandfetch.io/CRVO/w/400/h/400?c=1idopYfmtR7ZKg8QMud CervoMed Inc. Reports Q3 2026 Financial Results and Liquidity Update CervoMed Inc. reported a narrower net loss in Q3 2026, driven by lower operating expenses, and said grant revenue has ended. The company stated that its cash resources are insufficient to fund operations for the next 12 months. Starting a Phase 3 trial for its dementia with Lewy bodies program depends on securing additional funding or a strategic partnership. https://openbell.ai/news/AGIG:1794060248000 2026-11-07T14:04:08.000Z daily 0.9 https://cdn.brandfetch.io/AGIG/w/400/h/400?c=1idopYfmtR7ZKg8QMud Abundia Global Impact Group Reports 2026 Third Quarter Financial Results Abundia Global Impact Group reported third-quarter 2026 revenue of $2.32 million, up 50.9% year over year. Its operating loss narrowed to $3.38 million from $20.77 million a year earlier, while diluted loss per share improved to $0.08 from $0.62. The results were disclosed in the company’s 10-Q filed November 6, 2026. https://openbell.ai/news/SELF:1794060237000 2026-11-07T14:03:57.000Z daily 0.9 https://cdn.brandfetch.io/SELF/w/400/h/400?c=1idopYfmtR7ZKg8QMud Global Self Storage Reports Third Quarter 2026 Results Global Self Storage reported third-quarter 2026 revenue of $3.2 million, up 0.6% year over year, while net income fell 16.0% to $417,000, or $0.04 per diluted share. Same-store revenue increased 0.6%, attributed to higher rates for existing tenants; operating income rose 6.7% to $777,000, and operating expenses declined 1.2%. Same-store occupancy was 92.9% at September 30, 2026, and the company maintained its quarterly dividend at $0.0725 per common share.